160 related articles for article (PubMed ID: 17847890)
1. Victory for NICE as High Court rejects drugs firm complaints.
Evans O
Health Serv J; 2007 Aug; 117(6069):5. PubMed ID: 17847890
[No Abstract] [Full Text] [Related]
2. NICE stands firm, but the public must learn to respect rationing.
Mooney H
Health Serv J; 2007 Aug; 117(6070):12-3. PubMed ID: 17977221
[No Abstract] [Full Text] [Related]
3. Independent body calls for a change in drug policies.
Wise J
BMJ; 2012 Oct; 345():e7044. PubMed ID: 23078962
[No Abstract] [Full Text] [Related]
4. Data briefing. The NICE threshold.
Appleby J
Health Serv J; 2007 Sep; 117(6074):21. PubMed ID: 17970386
[No Abstract] [Full Text] [Related]
5. On avoiding a 'last resort'.
Donald A
Health Serv J; 2007 Sep; 117(6073):17. PubMed ID: 17972674
[No Abstract] [Full Text] [Related]
6. Britain to combat conflicts of interest in drug regulators.
Giles J
Nature; 2004 Nov; 432(7015):263. PubMed ID: 15549064
[No Abstract] [Full Text] [Related]
7. Triazolam licensing in UK.
Brahams D
Lancet; 1993 Jun; 341(8860):1587. PubMed ID: 8099654
[No Abstract] [Full Text] [Related]
8. NICE: a nightmare worth having?
Drummond M
Health Econ Policy Law; 2007 Apr; 2(Pt 2):203-8; discussion 217-21. PubMed ID: 18634663
[No Abstract] [Full Text] [Related]
9. Novartis challenges India's drug patent laws in Supreme Court.
Billingsley M
BMJ; 2012 Feb; 344():e1279. PubMed ID: 22354594
[No Abstract] [Full Text] [Related]
10. A response to Birch and Gafni--some reasons to be cheerful about NICE.
Gold M; Bryan S
Health Econ Policy Law; 2007 Apr; 2(Pt 2):209-16; discussion 217-21. PubMed ID: 18634664
[No Abstract] [Full Text] [Related]
11. A rational framework for decision making by the National Institute For Clinical Excellence (NICE).
Claxton K; Sculpher M; Drummond M
Lancet; 2002 Aug; 360(9334):711-5. PubMed ID: 12241891
[TBL] [Abstract][Full Text] [Related]
12. Impurities in organic synthetic drugs: a review of regulatory and toxicological considerations.
Mahoney K; Scales MD; Tucker ML
Adverse Drug React Toxicol Rev; 1993; 12(2):129-38. PubMed ID: 8357945
[No Abstract] [Full Text] [Related]
13. Consultation on rescheduling ketamine.
Cooper P
Vet Rec; 2014 Jan; 174(2):52. PubMed ID: 24413300
[No Abstract] [Full Text] [Related]
14. Lethal injection under fire: drug shortages and court challenges are causing lawmakers to review their states' method of execution.
Widgery A
State Legis; 2015 May; 41(5):30-1. PubMed ID: 25966509
[No Abstract] [Full Text] [Related]
15. Risky business.
Ment Health Today; 2005 May; ():12-3. PubMed ID: 15938578
[No Abstract] [Full Text] [Related]
16. Trying times at the FDA--the challenge of ensuring the safety of imported pharmaceuticals.
Schweitzer SO
N Engl J Med; 2008 Apr; 358(17):1773-7. PubMed ID: 18434648
[No Abstract] [Full Text] [Related]
17. The future of off-label marketing regulations in the post-Sorrell era.
Iraggi J
Seton Hall Law Rev; 2013; 43(3):1137-63. PubMed ID: 23802338
[No Abstract] [Full Text] [Related]
18. Sales of contaminated animal drugs halted.
Henkel J
FDA Consum; 1999; 33(5):34. PubMed ID: 10522171
[No Abstract] [Full Text] [Related]
19. Drug patent protection: how long is long enough?
Sibbald B
CMAJ; 2001 May; 164(9):1331. PubMed ID: 11341146
[No Abstract] [Full Text] [Related]
20. Drug and alcohol policy at the global level.
Anderson P
Drug Alcohol Rev; 2006 Nov; 25(6):485-7. PubMed ID: 17132568
[No Abstract] [Full Text] [Related]
[Next] [New Search]
